BioAtla Insider Buying Surge: CEO, CFO, and CMO Back Their Biotech
BioAtla insider moves: CEO, CFO, and CMO pile on shares while CMO locks in a long‑term RSU, signaling confidence in the clinical‑stage pipeline and a potential short‑term rally for the low‑price biotech.
4 minutes to read